About Septerna, Inc.
https://septerna.comSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
CEO
Jeffrey T. Finer
Compensation Summary
(Year 2024)
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:934.76K
IWM
Weight:0.02%
Shares:526.66K
XSU.TO
Weight:0.02%
Shares:526.66K
Summary
Showing Top 3 of 76
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:7M
Value:$187M
TRV GP V, LLC
Shares:6.22M
Value:$166.14M
DRIEHAUS CAPITAL MANAGEMENT LLC
Shares:4.92M
Value:$131.51M
Summary
Showing Top 3 of 86
About Septerna, Inc.
https://septerna.comSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $21.5M ▲ | $18.88M ▼ | $8.17M ▲ | 38.02% ▲ | $0.18 ▲ | $-9.48M ▲ |
| Q2-2025 | $119K ▼ | $29.1M ▲ | $-24.84M ▼ | -20.87K% ▼ | $-0.56 ▼ | $-28.57M ▼ |
| Q1-2025 | $219K ▲ | $26.13M ▲ | $-21.48M ▼ | -9.81K% ▼ | $-0.49 ▲ | $-25.51M ▼ |
| Q4-2024 | $212K ▲ | $24.93M ▲ | $-20.67M ▼ | -9.75K% ▲ | $-0.64 ▼ | $-24.33M ▼ |
| Q3-2024 | $176K | $22.73M | $-20.52M | -11.66K% | $-0.49 | $-22.19M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $474.35M ▲ | $606.65M ▲ | $217.92M ▲ | $388.73M ▲ |
| Q2-2025 | $326.56M ▼ | $415.23M ▼ | $37.67M ▲ | $377.56M ▼ |
| Q1-2025 | $336M ▼ | $434.02M ▼ | $33.75M ▼ | $400.27M ▼ |
| Q4-2024 | $350.92M ▲ | $456.55M ▲ | $36.51M ▼ | $420.05M ▲ |
| Q3-2024 | $130.53M | $174.28M | $261.69M | $-87.41M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.17M ▲ | $168.81M ▲ | $-38.39M ▼ | $263K ▼ | $130.68M ▲ | $168.79M ▲ |
| Q2-2025 | $-24.84M ▼ | $-20.29M ▲ | $-786K ▲ | $339K ▲ | $-20.73M ▲ | $-20.34M ▲ |
| Q1-2025 | $-21.48M ▼ | $-23.34M ▼ | $-4.87M ▲ | $66K ▼ | $-28.15M ▼ | $-23.73M ▼ |
| Q4-2024 | $-20.67M ▼ | $-20.96M ▼ | $-133.24M ▼ | $304.15M ▲ | $149.95M ▲ | $-21.57M ▼ |
| Q3-2024 | $-20.52M | $-16.81M | $-24.79M | $-1.32M | $-42.93M | $-17.39M |
CEO
Jeffrey T. Finer
Compensation Summary
(Year 2024)
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:934.76K
IWM
Weight:0.02%
Shares:526.66K
XSU.TO
Weight:0.02%
Shares:526.66K
Summary
Showing Top 3 of 76
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:7M
Value:$187M
TRV GP V, LLC
Shares:6.22M
Value:$166.14M
DRIEHAUS CAPITAL MANAGEMENT LLC
Shares:4.92M
Value:$131.51M
Summary
Showing Top 3 of 86